white
Sponsors
Aarhus University Hospital, Karolinska University Hospital, Amgen Inc., NewAmsterdam Pharma B.V., Harmony Biosciences LLC
Conditions
Acute laryngitisAnemia in subjects with sickle cell disease (SCD)Arrhythmogenic Cardiomyopathy (ACM)Brain tumorChemotherapy-induced Thrombocytopenia in Adult Subjects with GastrointestinalKidney transplant recipientsMigrainePancreatic
Phase 1
Phase 2
Thiamine against chronic rheumatoid arthritis fatigue
CompletedCTIS2022-500922-13-00
Start: 2023-02-16End: 2023-08-30Target: 40Updated: 2023-03-03
LiBRA – Lithium treatment to prevent cognitive impairment after brain radiotherapy.
RecruitingCTIS2023-504071-24-00
Start: 2023-11-07Target: 114Updated: 2025-10-06
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
Not yet recruitingCTIS2024-515202-84-00
Target: 66Updated: 2026-01-26
Statin Effect on ARrhythmogenic CardiomyopatHy disease progression
RecruitingCTIS2024-514643-28-00
Start: 2025-03-25Target: 102Updated: 2025-04-14
Phase 3
Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Active, not recruitingCTIS2023-507795-51-00
Start: 2022-05-17Target: 4094Updated: 2026-01-27
A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)
CompletedCTIS2023-507148-35-00
Start: 2019-10-03End: 2025-01-09Target: 60Updated: 2025-06-26
Corticosteroid in treatment of acute laryngitis among vocal professionals
Not yet recruitingCTIS2024-512192-12-00
Target: 70Updated: 2024-10-29
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients with Prader-Willi Syndrome
RecruitingCTIS2023-508307-21-00
Start: 2025-03-19Target: 115Updated: 2025-07-25